Benzinga | Nov 4, 2020 08:21AM EST

The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech Stocks Hitting 52-week Highs Nov. 3)

* Bio-Rad Laboratories, Inc. (NYSE:BIO)

* Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)

* BioLife Solutions Inc (NASDAQ:BLFS)

* BioLineRx ADR Representing 15 Ord Shs (NASDAQ:BLRX)(reacted to positive readout for its stem cell therapy to treat cancer)

* Halozyme Therapeutics, Inc. (NASDAQ:HALO)(reacted to its quarterly results)

* Idera Pharmaceuticals Inc (NASDAQ:IDRA)

* Inspire Medical Systems Inc (NYSE:INSP) ( reported strong results for the third quarter)

* Immunovant Inc (NASDAQ:IMVT)

* Scholar Rock Holding Corp (NASDAQ:SRRK)

* Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

* United Therapeutics Corporation (NASDAQ:UTHR)

Down In The Dumps

(Biotech Stocks Hitting 52-week Lows Nov. 3)

* Abeona Therapeutics Inc (NASDAQ:ABEO)

* Aprea Therapeutics Inc (NASDAQ:APRE)

* Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

* Benitec Biopharma Inc (NASDAQ:BNTC)

* Esperion Therapeutics Inc (NASDAQ:ESPR) (reacted to its quarterly results)

* Happiness Biotech Group Ltd (NASDAQ:HAPP)

* Jaguar Health Inc (NASDAQ:JAGX)

* Liminal BioSciences Inc (NASDAQ:LMNL)

* Nabriva Therapeutics PLC -- ADR (NASDAQ:NBRV)

* Neovasc Inc (NASDAQ:NVCN)

* Opthea Spon (NASDAQ:OPT)

* Silence Therapeutics ADR (NASDAQ:SLN)

* Titan Pharmaceuticals, Inc (NASDAQ:TTNP)

Stocks In Focus

Bristol-Myers Squibb Says Antitrust Waiting Period For Proposed Myokardia Acquisition Expires

Bristol-Myers Squibb Co (NYSE:BMY) said the waiting period under the HSR Act in connection with its previously announced tender offer to acquire all outstanding shares of Myokardia Inc (NASDAQ:MYOK) expired.

This satisfies one of the conditions necessary for the consummation of the transaction, and the consummation is now contingent on the tender of a majority of the outstanding shares of MyoKardia's common stock, as well as other customary closing conditions.

The tender is scheduled to expire by Nov. 16 at 11:59 pm.

Soleno Presents Positive Body Composition Data From a Late-stage Prader-Willi Syndrome Study

Soleno Therapeutics Inc (NASDAQ:SLNO) announced presentation of positive body composition data from its Phase 3 trial, evaluating once-daily diazoxide choline controlled-release tablets for patients with Prader-Willi Syndrome at the Obesity Society's ObesityWeek 2020 meeting.

The results showed significant reductions in fat mass after 13 weeks of double-blind treatment, a significant reduction in leptin and an increase in adiponectin, a cardioprotective hormone.

"The data presented to date show that DCCR has the potential to manage both behavioral and co-morbid metabolic components of PWS," said Parisa Salehi, a clinician at Seattle Children's Hospital.

Earnings

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) reported third-quarter revenues of $155.14 million, higher than $102.14 million last year. The earnings per share climbed from 54 cents to 74 cents, notably higher than the 30-cent per share consensus estimate. The company raised its guidance for full-year 2020.

The stock rallied 20.88% to $21.94 in after-hours trading.

Five Prime Therapeutics Inc's (NASDAQ:FPRX) third-quarter revenues fell from $2.984 million to $2.048 million. The loss per share, though narrowing from $1.03 to 74 cents, was wider than the consensus loss estimate of 60 cents per share.

The stock was down 10.79% to $4.30 in after-hours trading.

On The Radar

Clinical Readouts

vTv Therapeutics Inc (NASDAQ:VTVT) will make an oral presentation at the CTAD, providing a general study update and data on the baseline characteristics of patients enrolled in the ongoing phase 2 Elevage Study of azeliragon as a potential treatment for mild-probable Alzheimer's disease in adult patients who also have type 2 diabetes.

Earnings

Haemonetics Corporation (NYSE:HAE) (before the market open)

Aquestive Therapeutics Inc (NASDAQ:AQST) (after the close)

Anika Therapeutics Inc (NASDAQ:ANIK) (after the close)

Axonics Modulation Technologies Inc (NASDAQ:AXNX) (after the close)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) (after the close)

T2 Biosystems Inc (NASDAQ:TTOO) (after the close)

OraSure Technologies, Inc. (NASDAQ:OSUR) (after the close)

Hologic, Inc. (NASDAQ:HOLX) (after the close)

Otonomy Inc (NASDAQ:OTIC) (after the close)

SurModics, Inc. (NASDAQ:SRDX) (after the close)

Sangamo Therapeutics Inc (NASDAQ:SGMO) (after the close)

PRA Health Sciences Inc (NASDAQ:PRAH) (after the close)

Cytosorbents Corp (NASDAQ:CTSO) (after the close)

Lineage Cell Therapeutics Inc (NYSE:LCTX) (after the close)

Insulet Corporation (NASDAQ:PODD) (after the close)

Cytokinetics, Inc. (NASDAQ:CYTK) (after the close)

MannKind Corporation (NASDAQ:MNKD) (after the close)

Flexion Therapeutics Inc (NASDAQ:FLXN) (after the close)

DiaMedica Therapeutics Inc (NASDAQ:DMAC) (after the close)

Orthopediatrics Corp (NASDAQ:KIDS))

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

G1 Therapeutics Inc (NASDAQ:GTHX)

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

Other Events

The FDA is due to release the briefing document related to Biogen Inc's (NASDAQ:BIIB) BLA for aducanumab for the treatment of Alzheimer's disease.